These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9665362)

  • 1. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Frothingham R
    Arch Intern Med; 1998 Jul; 158(13):1470-2. PubMed ID: 9665362
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US.
    Lacey L; Mauskopf J; Lindrooth R; Pham S; Saag M; Sawyer W
    Pharmacoeconomics; 1999; 15 Suppl 1():23-37. PubMed ID: 10537440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.
    Cook J; Dasbach E; Coplan P; Markson L; Yin D; Meibohm A; Nguyen BY; Chodakewitz J; Mellors J
    AIDS Res Hum Retroviruses; 1999 Apr; 15(6):499-508. PubMed ID: 10221527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective.
    Lacey L; Youle M; Trueman P; Staszewski S; Schrappe M; Behrens M
    Pharmacoeconomics; 1999; 15 Suppl 1():39-53. PubMed ID: 10537441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing regimens in HIV infection. Canadian perspective.
    Lacey L; Hopkinson PK; Montaner J; Leblanc F; Gill MJ
    Pharmacoeconomics; 1999; 15 Suppl 1():55-66. PubMed ID: 10537442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-occupational postexposure prophylaxis for HIV: a systematic review.
    Bryant J; Baxter L; Hird S
    Health Technol Assess; 2009 Feb; 13(14):iii, ix-x, 1-60. PubMed ID: 19236820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of zidovudine to prevent mother-to-child transmission of HIV in sub-Saharan Africa.
    Mansergh G; Haddix AC; Steketee RW; Simonds RJ
    JAMA; 1998 Jul; 280(1):30-1. PubMed ID: 9660355
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemoprophylaxis after occupational exposure to human immunodeficiency virus in forensic autopsy.
    Kibayashi K; NG'walali PM; Tsunenari S
    Nihon Hoigaku Zasshi; 1998 Apr; 52(2):163-4. PubMed ID: 9711070
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost of preventing HIV infection after sexual exposure.
    Lindbloom EJ; Stevermer JJ
    J Fam Pract; 1998 Oct; 47(4):251-2. PubMed ID: 9789505
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa.
    Marseille E; Kahn JG; Saba J
    AIDS; 1998 May; 12(8):939-48. PubMed ID: 9631148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postexposure chemoprophylaxis for occupational exposure to HIV in the dental office.
    Chenoweth CE; Gobetti JP
    J Am Dent Assoc; 1997 Aug; 128(8):1135-9. PubMed ID: 9260424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report updates recommendations for health workers exposed to HIV.
    Am J Health Syst Pharm; 1998 Sep; 55(17):1755. PubMed ID: 9867409
    [No Abstract]   [Full Text] [Related]  

  • 16. Comment: cost-effective pharmaceutical care for HIV disease.
    Hoar ME
    Ann Pharmacother; 1998 Jun; 32(6):716-7. PubMed ID: 9640494
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV.
    Pinkerton SD; Holtgrave DR; Bloom FR
    AIDS; 1998 Jun; 12(9):1067-78. PubMed ID: 9662204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of a rapid HIV test for evaluation of the source patient after occupational exposure of healthcare workers.
    Puro V; Francisci D; Sighinolfi L; Civljak R; Belfiori B; Deparis P; Roda R; Modestino R; Ghinelli F; Ippolito G
    J Hosp Infect; 2004 Jun; 57(2):179-82. PubMed ID: 15183251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mother-to-child HIV transmission debate.
    Hussey G; Fransman D; McGillivray G; Reynolds L; Jacobs M; Power D; Burgess J; Eley B; Woods D; Coetzee N; Coetzee E; Anthony J; Maartens G; Schaaf S; Cotton M; Theron G
    S Afr Med J; 1999 Feb; 89(2):103-4. PubMed ID: 10191847
    [No Abstract]   [Full Text] [Related]  

  • 20. The mother-to-child HIV transmission debate.
    Beyers N; Cotton MF; Donald PR; Gie RP; Henning PA; Hesseling PB; Kirsten GF; Kling S; Nel ED; Pieper CH; Ravenscroft A; Schaaf HS; Schoeman JF; Smith J; van Buuren AJ; van der Merwe PL; van Schalkwyk HJ; Wessels G
    S Afr Med J; 1999 Feb; 89(2):104, 106. PubMed ID: 10357681
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.